CoPAN — CoA Synthase Protein-Associated Neurodegeneration, designated NBIA6, OMIM #615643, a rare autosomal recessive neurodegenerative disorder caused by biallelic mutations in COASY (coenzyme A synthase gene, chromosome 17q21.2; COASY encodes the bifunctional enzyme coenzyme A synthase, which catalyzes the final two enzymatic steps of coenzyme A (CoA) biosynthesis from pantothenate — first, phosphopantetheine adenylyltransferase [PPAT] activity converts 4'-phosphopantetheine to dephospho-CoA by adenylation; second, dephospho-CoA kinase [DPCK] activity phosphorylates dephospho-CoA to yield the final CoA product; COASY thus sits at the terminal end of the pantothenate kinase / CoA biosynthesis pathway, downstream of pantothenate kinase [PANK2 — the enzyme deficient in the related NBIA disorder PKAN, pantothenate kinase-associated neurodegeneration], phosphopantothenate-cysteine synthetase [PPCS], phosphopantothenoylcysteine decarboxylase [PPCDC], and phosphopantetheine adenylyltransferase [PPAT], with COASY performing the final adenylation and phosphorylation steps to generate CoA; CoA is the universal acyl group carrier essential for the tricarboxylic acid cycle, fatty acid oxidation and synthesis, histone acetylation, acetyl-CoA metabolism, and numerous other fundamental metabolic processes; COASY mutations causing CoPAN impair the bifunctional enzyme's catalytic activities, reducing CoA biosynthesis and disrupting CoA-dependent metabolic pathways particularly in neurons with high metabolic demands; the mechanism by which COASY deficiency leads to brain iron accumulation in globus pallidus and substantia nigra — the pathognomonic NBIA feature shared across the NBIA disease group — remains incompletely characterized but may involve dysregulation of iron-sulfur cluster assembly or CoA-dependent iron metabolism processes; CoPAN is among the rarest of the NBIA disorders, with fewer than 30 patients described globally as of 2025, most identified through whole-exome sequencing in children and adolescents presenting with an NBIA clinical picture); the clinical phenotype of CoPAN is characterized by childhood or adolescent onset (range reported: 2–17 years at symptom onset), with spastic paraplegia as a frequent early feature (lower limb spasticity, hyperreflexia, extensor plantar responses — the spastic component distinguishes CoPAN from some other NBIA subtypes), dystonia (focal initially, becoming generalized — upper limb action dystonia and oromandibular dystonia are reported; dystonia may be the predominant feature in some patients), dysarthria (motor speech impairment — present early and progresses; in severe cases becomes anarthria), cognitive deterioration (intellectual regression from baseline or delayed intellectual development — progressive cognitive decline across the disease course), optic atrophy (documented in a subset of affected individuals — visual acuity loss, optic disc pallor on fundoscopy), and brain iron accumulation on MRI (T2 and SWI/GRE hypointensity in globus pallidus — the hallmark NBIA neuroimaging finding — with substantia nigra involvement documented in some cases; the distribution of iron accumulation and any associated T2 hyperintensity pattern differs from PKAN's characteristic "eye of the tiger" sign, though overlap with other NBIA subtypes requires molecular confirmation for definitive diagnosis); the clinical overlap with PKAN (pantothenate kinase — upstream step in the same CoA biosynthesis pathway) and other NBIA subtypes (MPAN [C19orf12 mutations], BPAN [WDR45], neuroferritinopathy [FTL], aceruloplasminemia, and others in the NBIA classification) means that COASY molecular testing by whole-exome sequencing or NBIA gene panel is required for diagnosis; no disease-modifying therapy is available; care technology platforms monitor neurological assessments (motor function — spasticity rating [Modified Ashworth Scale, Tardieu Scale], dystonia rating scales [Burke-Fahn-Marsden Dystonia Rating Scale / BFMDRS]), serial brain MRI intervals (iron accumulation in globus pallidus — T2/SWI protocol), visual function (ophthalmology — optic atrophy surveillance, visual evoked potentials), speech and language therapy sessions (dysarthria progression and communication adaptation), spasticity management medication adherence (baclofen — oral and intrathecal where used; tizanidine; physiotherapy coordination), antidystonic therapy adherence (trihexyphenidyl, tetrabenazine, botulinum toxin injection records), cognitive function testing (progressive deterioration tracking — neuropsychological assessments), occupational therapy and physiotherapy coordination, and genetic counseling documentation (autosomal recessive — sibling and family testing).
CoPAN technology platforms — encompassing the molecular genetics laboratories where COASY biallelic mutation identification by whole-exome sequencing, targeted NBIA gene panel, or Sanger sequencing confirms the molecular diagnosis in an ultra-rare disease with fewer than 30 known patients globally; the motor function assessment platforms — Modified Ashworth Scale spasticity scoring systems, Tardieu Scale recording tools, Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) movement and disability subscale records, dystonia distribution mapping tools — tracking the spasticity and dystonia trajectory across the CoPAN disease course; the neuroimaging surveillance platforms — serial brain MRI scheduling systems with T2 and SWI/GRE protocol coordination, neuroradiology reporting platforms, globus pallidus and substantia nigra iron accumulation documentation tools — managing the longitudinal MRI required to track NBIA brain iron deposition in CoPAN; the ophthalmological surveillance platforms — visual acuity assessment scheduling tools, fundoscopy report platforms, visual evoked potential (VEP) scheduling and result records, optic atrophy grading documentation systems — coordinating the visual function monitoring required given the optic atrophy risk documented in CoPAN; the speech and language therapy (SLP) coordination platforms — dysarthria assessment scheduling tools, SLP session records, augmentative and alternative communication (AAC) evaluation and device coordination tools, serial dysarthria progression documentation systems — supporting the communication management as dysarthria progresses toward anarthria in advanced CoPAN; the cognitive function testing platforms — neuropsychological battery scheduling systems, cognitive assessment records documenting progressive intellectual deterioration, educational and vocational support coordination platforms for pediatric and adolescent patients; the spasticity and dystonia pharmacological management platforms — baclofen prescription and dose titration records (oral and intrathecal pump coordination where ITB pump used), tizanidine prescription records, trihexyphenidyl dose records, tetrabenazine adherence monitoring platforms, botulinum toxin injection scheduling and record platforms for focal dystonia management; the physiotherapy and occupational therapy coordination platforms — physiotherapy session scheduling and records (spasticity stretching program, exercise therapy, mobility aids coordination), occupational therapy session and adaptive equipment records; and the genetic counseling platforms managing the autosomal recessive inheritance implications, sibling testing coordination, and family genetic counseling — must maintain availability and performance standards matched to the pediatric neurological assessment urgency, motor function monitoring requirements, and multi-specialty coordination demands of contemporary CoPAN management. This guide explains why CoPAN tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the neurological assessment urgency and spasticity-dystonia management requirements of CoPAN care.
Why CoPAN Tech Platforms Require Specialized Monitoring Attention
CoPAN management is defined by several clinically urgent platform requirements: the diagnostic molecular testing urgency — CoPAN is an ultra-rare diagnosis confirmed by COASY biallelic mutation identification; in a child presenting with spastic paraplegia, dystonia, and globus pallidus T2 hypointensity on MRI, molecular testing platform availability is required at each step of the diagnostic evaluation; the motor function assessment urgency — spasticity and dystonia are the primary management targets in CoPAN, and serial spasticity rating (Modified Ashworth, Tardieu) and dystonia rating scale (BFMDRS) records are required to guide baclofen dose titration, assess tetrabenazine or trihexyphenidyl response, and document the trajectory for intrathecal baclofen pump consideration; the ophthalmological surveillance urgency — optic atrophy has been documented in a subset of CoPAN patients, and visual function monitoring with serial visual acuity assessment, fundoscopy, and VEP requires scheduling platform availability to detect and document visual loss that affects quality of life and educational planning for affected children and adolescents; the cognitive deterioration monitoring urgency — CoPAN causes progressive cognitive decline from baseline intellectual function or superimposed on baseline intellectual disability; serial cognitive assessment requires scheduling platform availability to document the trajectory that informs educational support, adaptive technology needs, and guardianship planning; the genetic counseling and sibling testing urgency — CoPAN is autosomal recessive (carrier parents each have a 25% risk of an affected child with each pregnancy; unaffected siblings have a 2/3 probability of being carriers); sibling testing and carrier testing for extended family members requires genetic counseling platform availability.
Molecular genetic testing platforms establish COASY biallelic mutation confirmation and CoPAN diagnosis. Whole-exome sequencing and NBIA gene panel testing identify COASY mutations and enable family cascade carrier testing. Monitor at 1-minute intervals during laboratory hours.
Motor function assessment platforms capture serial spasticity and dystonia rating scale records. Modified Ashworth Scale, Tardieu Scale, and BFMDRS trajectories require scheduling platform availability for serial assessment. Monitor at 1-minute intervals during clinical hours.
Ophthalmological surveillance platforms coordinate visual acuity, fundoscopy, and VEP monitoring. Optic atrophy surveillance requires scheduling platform availability at each ophthalmology review interval. Monitor at 1-minute intervals during clinical hours.
Cognitive function testing platforms document progressive intellectual deterioration. Serial neuropsychological assessments require platform availability at each evaluation interval. Monitor at 1-minute intervals during clinical hours.
Neuroimaging surveillance platforms coordinate serial brain MRI with T2/SWI iron tracking. Globus pallidus and substantia nigra iron accumulation progression requires scheduling platform availability. Monitor at 1-minute intervals during clinical hours.
Genetic counseling and family testing platforms coordinate autosomal recessive sibling testing. Sibling and family carrier testing records require coordination platform availability. Monitor at 1-minute intervals during clinical hours.
What to Monitor on a CoPAN Tech Platform
Molecular Genetic Testing — COASY Biallelic Mutation Identification
Monitor COASY molecular testing and variant characterization records (whole-exome sequencing records identifying biallelic COASY mutations — compound heterozygous or homozygous pathogenic variants in COASY; NBIA gene panel testing records — panels including COASY alongside PANK2, C19orf12, WDR45, FTL, CP, FA2H, ATP13A2, PLA2G6, DCAF17, and other NBIA genes; Sanger sequencing confirmation records for identified COASY variants; ACMG variant classification records — variant pathogenicity documentation based on COASY functional data and population frequency; functional CoA synthase enzymatic activity records where performed — PPAT and DPCK enzymatic activity quantification in patient-derived cells confirming the functional impact of COASY mutations; RNA studies records where splice variant effects require transcriptional characterization; parental carrier testing records — confirming biallelic inheritance from carrier parents), genetic counseling documentation (autosomal recessive inheritance counseling — both parents are obligate carriers; 25% recurrence risk for each future pregnancy; 2/3 probability that each unaffected sibling is a carrier; prenatal diagnosis options documentation — CVS or amniocentesis for future pregnancies if the COASY mutation pair is confirmed; preimplantation genetic diagnosis discussion records; cascade carrier testing referrals for extended family members), and CoPAN and NBIA registry records (NBIA Disorders Association patient registry enrollment; CoPAN natural history registry records where available — extremely limited given the ultra-rare disease prevalence of fewer than 30 known patients globally; expert center referral records — referral to NBIA specialist centers and clinicians with CoPAN expertise) at 1-minute intervals during laboratory hours. Alert immediately — COASY molecular testing platform failures during the genetic diagnostic workup of a 10-year-old presenting with progressive lower limb spasticity, action dystonia of the upper limbs, dysarthria, and bilateral globus pallidus T2/SWI hypointensity on brain MRI, when COASY biallelic mutation identification would confirm the CoPAN diagnosis, direct NBIA registry enrollment, initiate sibling and parental carrier testing, guide the motor function assessment protocol with spasticity and dystonia rating scales appropriate for NBIA, and enable referral to the international community of CoPAN-treating neurologists.
Motor Function Assessment — Spasticity and Dystonia Rating Scales
Monitor spasticity assessment records (Modified Ashworth Scale [MAS] serial records — muscle tone grading across lower limbs [hip flexors, knee flexors, ankle plantar flexors] and upper limbs as disease progresses; MAS scores at each clinical review documenting the trajectory from mild to moderate to severe spasticity; Tardieu Scale records — a velocity-dependent spasticity assessment capturing spastic catch angle and muscle reaction grade — particularly useful for distinguishing spasticity from contracture in CoPAN-affected limbs; serial Tardieu scores at each physiotherapy and neurology review; functional spasticity impact records — walking ability documentation [unaided ambulation, walking aid use, wheelchair dependence milestones], stair climbing capacity, ADL functional spasticity interference scores; intrathecal baclofen pump candidate assessment records — pump implantation criteria documentation, baclofen trial response records, surgical assessment records where ITB pump considered for severe spasticity refractory to oral agents), dystonia assessment records (Burke-Fahn-Marsden Dystonia Rating Scale [BFMDRS] movement subscale records — body region involvement mapping across eyes, mouth, speech, neck, trunk, upper limbs, and lower limbs; BFMDRS disability subscale records — speech, swallowing, handwriting, hygiene, dressing, feeding, and walking disability scores; serial BFMDRS records at 6-month intervals documenting dystonia evolution from focal to generalized; dystonia distribution characterization records — focal oromandibular dystonia, upper limb action dystonia, lower limb dystonia affecting gait; Dystonia Disability Scale records where used; dystonia trigger documentation — action-induced versus posture-specific patterns; botulinum toxin injection response records for accessible focal dystonia), and functional disability records (Gross Motor Function Classification System [GMFCS] records for pediatric patients — functional mobility level classification; Functional Independence Measure for Children [WeeFIM] records; ADL assessment records; mobility aid and wheelchair assessment records; palliative care and comfort-focused care coordination records for advanced-stage CoPAN patients) at 1-minute intervals during clinical hours. Alert immediately — motor function assessment platform failures preventing the neurologist from accessing the serial Modified Ashworth Scale spasticity score trajectory and the current BFMDRS dystonia rating for a 15-year-old CoPAN patient presenting for a baclofen dose review and trihexyphenidyl response assessment, when the serial spasticity and dystonia records documenting trajectory over 24 months inform whether baclofen dose escalation is warranted, whether trihexyphenidyl has produced sufficient dystonia benefit to justify dose continuation, and whether the patient meets criteria for intrathecal baclofen pump assessment referral.
Ophthalmological Surveillance — Optic Atrophy Monitoring
Monitor visual acuity assessment records (serial best-corrected visual acuity records — LogMAR acuity at each ophthalmology review; contrast sensitivity records where performed; color vision assessment records; visual acuity trajectory documentation — rate of visual loss over time; low vision referral records where visual acuity falls below functional thresholds), fundoscopy and optic disc assessment records (fundoscopy records at each ophthalmology review — optic disc appearance, color, and cupping documentation; optic disc pallor grading records — temporal pallor [early optic atrophy pattern], diffuse pallor [moderate-severe optic atrophy]; cup-to-disc ratio records; retinal nerve fiber layer [RNFL] optical coherence tomography [OCT] records — RNFL thinning as an early optic atrophy marker preceding visual acuity loss; serial OCT records documenting RNFL progression), visual evoked potential records (pattern VEP records — P100 latency and amplitude documenting optic nerve conduction integrity; VEP results at each surveillance interval — prolonged P100 latency and reduced amplitude documenting optic neuropathy; VEP-clinical correlation records — VEP documentation in patients without yet-detected fundoscopic optic atrophy to identify subclinical optic nerve dysfunction), and low vision and rehabilitation records (low vision aid prescription records — magnifiers, spectacle-mounted aids; educational accommodation records for school-age CoPAN patients with visual impairment — large print, electronic visual aids, screen magnification; orientation and mobility assessment records where visual impairment is functionally significant) at 1-minute intervals during clinical hours.
Cognitive Function Testing — Progressive Intellectual Deterioration Monitoring
Monitor serial cognitive assessment records (neuropsychological battery scheduling and result records — comprehensive cognitive assessment appropriate for age and pre-morbid developmental level; Wechsler Intelligence Scale records [WISC for pediatric patients, WAIS for adolescents and adults] — Full Scale IQ, Verbal Comprehension, Perceptual Reasoning, Working Memory, Processing Speed indices documenting regression from baseline; attention and executive function records — Trail Making Test, Stroop, BRIEF parent/teacher report for pediatric patients; memory assessment records — verbal and visual memory, working memory; visuospatial and visuoconstructive records), adaptive behavior assessment records (Vineland Adaptive Behavior Scales records — communication, daily living skills, socialization, motor skills composite documenting adaptive function trajectory; ABAS records where used; educational assessment records — IEP documentation for school-age patients, special educational needs assessment records), and educational and vocational support coordination records (special educational needs assessment and coordination records — learning support plan documentation, educational psychologist report records; assistive technology assessment records — AAC, switch access, gaze-based communication technology where severe dysarthria precludes verbal communication; transition planning records for adolescent CoPAN patients — post-school support coordination, guardianship assessment where cognitive impairment requires protective legal arrangements) at 1-minute intervals during clinical hours.
Neuroimaging Surveillance — T2/SWI Iron Tracking in Globus Pallidus and Substantia Nigra
Monitor serial brain MRI scheduling and result records (routine surveillance brain MRI scheduling — annual or biannual based on disease stage and rate of neurological progression; brain MRI protocol records — T2-weighted and SWI/GRE sequences required for NBIA iron assessment; brain MRI result documentation — T2 hypointensity in globus pallidus [bilateral, graded mild/moderate/severe relative to adjacent white matter], SWI blooming artifact in globus pallidus confirming paramagnetic iron deposition; substantia nigra T2 hypointensity documentation where present; any T2 hyperintensity within iron-hypointense regions [overlapping signal change] — pattern differing from PKAN's "eye of the tiger" sign; volumetric brain MRI records for cortical and white matter change documentation; serial iron progression grading across all available MRI dates), neuroradiology coordination records (neuroradiology reporting records; child neurology and movement disorder interpretation records comparing current and prior MRI; NBIA neuroradiologist consultation records where specialist neuroimaging review required), and neuroimaging-clinical correlation records (correlation of imaging iron progression with motor function rating scale trajectory; iron accumulation severity correlation with spasticity and dystonia severity; neuroimaging documentation for CoPAN natural history registry contribution; neuroimaging records used in communication with the ultra-rare disease specialist community) at 1-minute intervals during clinical hours.
Spasticity and Dystonia Pharmacological Management
Monitor spasticity management medication records (baclofen oral prescription and dose titration records — starting dose, dose escalation records, target dose documentation for spasticity management; treatment response records — MAS and Tardieu scale response at current baclofen dose; adverse effects monitoring records — sedation, weakness, functional trade-offs from spasticity reduction; intrathecal baclofen [ITB] pump implantation and programming records where ITB pump used — pump refill scheduling records, pump programming settings, dose change records, pump complication monitoring records [ITB withdrawal risk monitoring]; tizanidine prescription records where used as alternative or adjunct to baclofen; baclofen and tizanidine drug interaction records), dystonia management medication records (trihexyphenidyl dose titration records — anticholinergic burden monitoring [dry mouth, constipation, urinary retention, cognitive anticholinergic effects — particularly relevant given progressive cognitive impairment in CoPAN]; tetrabenazine prescription and adherence records where used for dystonia — monoamine depletion approach; treatment response records at BFMDRS review; adverse effects monitoring records [depression, sedation, parkinsonism — all of which complicate the CoPAN neurological picture]; deutetrabenazine records where used as tetrabenazine alternative; botulinum toxin injection records for focal dystonia — injection site, toxin dose, injection interval, response assessment; clonazepam records where used as adjunct), and physiotherapy and orthotic management records (physiotherapy session scheduling and records — spasticity stretching program, passive range of motion, active exercise within capability; AFO [ankle-foot orthosis] fitting and review records — orthosis for spastic foot drop; orthotic prescription and review records; standing frame and postural management records for non-ambulant patients; wheelchair seating and positioning records for patients dependent on wheelchair) at 1-minute intervals during clinical hours.
Speech and Language Therapy and Communication Adaptation
Monitor SLP assessment and session records (SLP scheduling and session records — dysarthria assessment using standardized tools [FDA-2, Robertson Dysarthria Profile]; dysarthria severity grading records [mild/moderate/severe/anarthria]; intelligibility assessment records — Percentage Consonants Correct, Connected Speech Intelligibility; communication effectiveness records; serial SLP records at 6-month intervals documenting dysarthria progression; SLP session content records — articulation therapy, breath support, rate control, communication strategies), augmentative and alternative communication records (AAC evaluation records — low-tech and high-tech AAC assessment; AAC device prescription records — speech-generating device [SGD] prescription, dedicated device versus app-based AAC; partner-assisted scanning records where motor impairment limits independent access; eye-gaze AAC system records where severe motor impairment requires gaze-based access; AAC device programming and vocabulary records; voice banking records where initiated while residual intelligible speech remains — Message Banking and ModelTalker records capturing natural voice samples for later AAC voice output), and feeding and dysphagia management records (clinical swallowing evaluation scheduling and result records — dysphagia present in some CoPAN patients, particularly with oromandibular dystonia and severe dysarthria; modified barium swallow study records; texture modification recommendations records; PEG tube assessment referral records where dysphagia progresses to aspiration risk requiring enteral feeding) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. CoPAN management coordinates across molecular genetics, pediatric neurology, movement disorder specialists, neuroradiology, ophthalmology, neuropsychology, speech and language therapy, physiotherapy, occupational therapy, educational services, and NBIA rare disease registries — authentication failures block the multi-specialty team during clinical encounters where serial motor function rating scale records, cognitive assessment trajectory data, MRI iron progression records, ophthalmological surveillance results, and genetic testing status must be simultaneously accessible.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, motor function assessment systems, ophthalmological surveillance platforms, cognitive testing tools, neuroimaging scheduling systems, spasticity and dystonia management records, SLP coordination tools, and genetic counseling platforms. Certificate errors disrupting access to baclofen dose titration records or BFMDRS dystonia score trajectory during a motor function review encounter create direct patient care quality risks.
HIPAA and Rare Disease Privacy Considerations for CoPAN
CoPAN technology platforms handle molecular genetic records (COASY biallelic mutations — autosomal recessive condition with carrier implications for both parents and 25% recurrence risk for future pregnancies, and 2/3 carrier probability for unaffected siblings — requiring special disclosure protocols), neuroimaging records (serial brain MRI with globus pallidus and substantia nigra iron accumulation — sensitive neurological disease progression documentation in a child or adolescent), motor function rating scale records (Modified Ashworth, Tardieu, BFMDRS serial scores documenting progressive spasticity and dystonia disability), cognitive function testing records (serial neuropsychological assessments documenting intellectual deterioration — particularly sensitive given the pediatric/adolescent patient population), ophthalmological surveillance records (visual acuity and optic atrophy progression — visual disability documentation), educational assessment and IEP records (special educational needs documentation — educational records with overlapping FERPA/HIPAA considerations), and pharmacological management records across the CoPAN care trajectory.
Alerting Strategy for CoPAN Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: COASY biallelic mutation identification — the diagnosis initiating sibling carrier testing, family counseling, NBIA registry enrollment, and the motor assessment and ophthalmological surveillance protocol.
Immediate clinical-hours alerting for motor function assessment platforms: Serial Modified Ashworth, Tardieu, and BFMDRS records — spasticity and dystonia trajectory documentation requires scheduling platform availability at each neurology review.
Immediate clinical-hours alerting for ophthalmological surveillance platforms: Visual acuity, fundoscopy, OCT, and VEP records — optic atrophy surveillance scheduling and result access.
Immediate clinical-hours alerting for cognitive function testing platforms: Serial neuropsychological assessments — intellectual deterioration trajectory documentation for educational planning and capacity assessment.
Immediate clinical-hours alerting for neuroimaging surveillance scheduling tools: Serial brain MRI with T2/SWI iron tracking — globus pallidus and substantia nigra accumulation progression.
Immediate clinical-hours alerting for spasticity and dystonia pharmacological management platforms: Baclofen, tizanidine, trihexyphenidyl, tetrabenazine, and botulinum toxin records — medication adherence and treatment response documentation.
Immediate clinical-hours alerting for SLP and dysphagia management platforms: Dysarthria progression records, AAC coordination, and dysphagia assessment scheduling.
Immediate clinical-hours alerting for genetic counseling and family cascade testing platforms: Sibling carrier testing coordination and family genetic counseling records.
Sustained-failure alert (10–15 minutes): NBIA patient registry, physiotherapy and occupational therapy coordination records, and educational support coordination platforms.
30-day advance warning: SSL certificates across all platforms.
Status Page for CoPAN Care Team Communication
A real-time status page gives molecular genetics laboratories, pediatric neurologists and movement disorder specialists, neuroradiologists, ophthalmologists and neuro-ophthalmologists, neuropsychologists, speech and language therapists, physiotherapists, occupational therapists, educational services, genetic counselors, NBIA rare disease registry coordinators, and family caregivers of affected children and adolescents immediate platform visibility without requiring inbound IT support contact.
Vigilmon Setup for CoPAN Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | COASY molecular testing and biallelic mutation identification | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling, sibling carrier testing, family cascade | 1 min | Slack + PagerDuty (lab hours) | | Modified Ashworth Scale and Tardieu spasticity records | 1 min | Slack + PagerDuty (clinical hours) | | BFMDRS dystonia rating and disability subscale records | 1 min | Slack + PagerDuty (clinical hours) | | Intrathecal baclofen pump programming and refill records | 1 min | Slack + PagerDuty (clinical hours) | | Trihexyphenidyl and tetrabenazine dystonia management records | 1 min | Slack + PagerDuty (clinical hours) | | Botulinum toxin injection records (focal dystonia) | 1 min | Slack + PagerDuty (clinical hours) | | Visual acuity, fundoscopy, OCT, and VEP scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Serial neuropsychological assessments and cognitive monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Educational and adaptive support coordination | 1 min | Slack + PagerDuty (clinical hours) | | Serial brain MRI scheduling and T2/SWI iron tracking | 1 min | Slack + PagerDuty (clinical hours) | | Neuroradiology reporting and iron progression documentation | 1 min | Slack + PagerDuty (clinical hours) | | SLP and dysarthria assessment scheduling | 1 min | Slack + PagerDuty (clinical hours) | | AAC evaluation and device coordination records | 1 min | Slack + PagerDuty (clinical hours) | | Physiotherapy session scheduling and spasticity program | 2 min | Slack (clinical hours) | | NBIA patient registry and natural history contribution | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure COASY molecular testing platforms with immediate laboratory-hours alerting — in an ultra-rare disease with fewer than 30 patients globally, confirmatory molecular diagnosis drives the entire multi-specialty care pathway
- Add genetic counseling and sibling carrier testing coordination platforms with immediate laboratory-hours alerting
- Configure Modified Ashworth Scale and Tardieu spasticity record platforms with immediate clinical-hours alerting — serial spasticity trajectory drives baclofen and intrathecal pump management decisions
- Add BFMDRS dystonia rating and disability subscale records with immediate clinical-hours alerting
- Configure intrathecal baclofen pump programming and refill records with immediate clinical-hours alerting — ITB pump dose records are patient-safety-critical
- Add trihexyphenidyl, tetrabenazine, and botulinum toxin dystonia management records with immediate clinical-hours alerting
- Configure visual acuity, fundoscopy, OCT, and VEP scheduling with immediate clinical-hours alerting — optic atrophy surveillance requires platform availability at each ophthalmology review
- Add serial neuropsychological assessments with immediate clinical-hours alerting — intellectual deterioration trajectory documentation informs educational support and capacity planning
- Configure educational and adaptive support coordination platforms with immediate clinical-hours alerting
- Add serial brain MRI scheduling and T2/SWI iron tracking with immediate clinical-hours alerting
- Configure SLP and dysarthria assessment scheduling with immediate clinical-hours alerting
- Add AAC evaluation and device coordination records with immediate clinical-hours alerting
- Configure physiotherapy session and spasticity program records with sustained-failure alerting
- Add NBIA registry and natural history contribution records with sustained-failure alerting — CoPAN's ultra-rare status means each patient's data is a significant natural history contribution
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to CoPAN neurology downtime protocols, ophthalmology clinic procedures, and educational support coordination workflows
Conclusion
CoPAN technology platforms are embedded in clinical decisions where motor function assessment platform availability — when the pediatric neurologist must access the serial Modified Ashworth Scale spasticity scores and BFMDRS dystonia trajectory for a 13-year-old CoPAN patient presenting for a baclofen and trihexyphenidyl review, and the family reports that lower limb spasticity has worsened over the past 6 months with falls increasing and walking distance declining, but the caregiver is uncertain whether the dystonia has changed — cannot be disrupted by assessment platform failures that withhold the serial spasticity and dystonia rating scale records at the moment when the clinical decision between baclofen dose escalation, trihexyphenidyl dose adjustment, and intrathecal baclofen pump referral depends on the documented trajectory over 18 months of serial assessments; where ophthalmological surveillance platform availability — when the ophthalmologist must access the prior visual acuity records and OCT RNFL thickness data for an 11-year-old CoPAN patient attending annual optic atrophy surveillance, and the prior OCT from 12 months ago showed borderline-low RNFL thickness in the temporal quadrant — is the platform access that determines whether the current OCT representing a 15% further decline in RNFL thickness triggers a low vision referral and educational accommodation update, or whether the RNFL value, without the prior comparison, would be interpreted as within normal variation; where cognitive function testing platform availability — when the educational psychologist must access the serial neuropsychological battery records for a 16-year-old CoPAN patient to prepare a post-school transition plan, and the most recent Vineland Adaptive Behavior Scales composite score and Wechsler index profile documenting the trajectory of intellectual deterioration across three assessments — is the platform access that enables the educational psychologist to project support needs and distinguish the accommodation requirements of a stable intellectual disability from the escalating support needs of a patient with demonstrably progressive cognitive decline; and where genetic counseling platform availability — when the genetic counselor must access the COASY biallelic variant records and family pedigree to prepare for a carrier testing result disclosure to the proband's unaffected 17-year-old sibling — is the platform availability that ensures the counselor can present the COASY variant pair, the inheritance model, the confirmed carrier status result, and the reproductive counseling implications with the complete family record context.
Uptime monitoring gives CoPAN tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, pediatric neurologists, movement disorder specialists, ophthalmologists, neuropsychologists, speech therapists, physiotherapists, educational services, genetic counselors, and the ultra-rare disease community that platform operational reliability matches the neurological assessment urgency, spasticity-dystonia management precision, and ophthalmological surveillance requirements of contemporary CoPAN care.
Start monitoring your CoPAN care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #CoPAN #COASY #NBIA6 #NBIAdisorder #CoAsynthase #pantothenate #ironaccumulation #globuspallidus #spasticparaplegia #dystonia #dysarthria #opticatrophy #cognitivedecline #baclofen #trihexyphenidyl #tetrabenazine #botulinumtoxin #raredisease #pediatricneurology #HIPAA #healthtech #digitalhealth #uptime #sre